Sensei Biotherapeutics, Inc. - Common Stock (SNSE)

Newman Ferrara LLP announced today that the firm is conducting investigations on behalf of shareholders of Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) (“Sensei” or the “Company”). The investigations concern whether certain of the Sensei’s officers and directors breached their fiduciary duties to shareholders, by, among other things: (i) engaging in self-dealing; (ii) affirmatively approving transactions that harmed the Company; and (iii) failing to provide sufficient oversight of the Company’s business practices.

SLIEMA, Malta, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Apeiron Investment Group Ltd. (together with its affiliates “AIG”), one of the largest shareholders of Sensei Biotherapeutics, Inc. (“Sensei” or the “Company”) (NASDAQ: SNSE), which beneficially owns approximately 11.2% of the outstanding shares of Sensei’s stock, today announced that it has sent the following letter to Sensei’s Board of Directors (the “Board”).